Repligen Corporation

292 articles about Repligen Corporation

• UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report

  11/14/2023

  Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.

• Repligen Announces Publication of the Company’s 2022 Sustainability Report

  11/14/2023

  Repligen Corporation today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures.

• Repligen Corporation to Present at Upcoming Investor Conferences - November 7, 2023

  11/7/2023

  Repligen Corporation today announced that it will be presenting at two upcoming investor conferences.

• Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

  10/31/2023

  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023.

• Repligen to Report Third Quarter 2023 Financial Results

  10/17/2023

  Repligen Corporation announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31, 2023.

• Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

  10/2/2023

  Repligen Corporation today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.

• Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova

  9/26/2023

  Repligen Corporation today announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden.

• Repligen Appoints Jason K. Garland as Chief Financial Officer

  9/12/2023

  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), effective September 25, 2023.

• Repligen Corporation to Present at Wells Fargo Healthcare Conference

  9/1/2023

  Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 6 -8 in Boston.

• Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification

  8/17/2023

  Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell ® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

• Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

  8/2/2023

  Repligen Corporation today reported financial results for its second quarter (Q2) and first half (H1) of 2023, covering the three- and six-month fiscal periods ended June 30, 2023.

• Repligen to Report Second Quarter 2023 Financial ResultsWebcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET

  7/19/2023

  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2, 2023.

• Repligen Corporation to Present at Upcoming June 2023 Investor Conferences

  5/31/2023

  Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be presenting at two upcoming investor conferences.

• Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

  5/2/2023

  Repligen Corporation today reported financial results for its first fiscal quarter ended March 31, 2023.

• Repligen to Report First Quarter 2023 Financial Results

  4/18/2023

  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023.

• Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum - March 14, 2023

  3/14/2023

  Repligen Corporation today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22. 

• Repligen Reports Fourth Quarter and Full Year 2022 Financial Results

  2/22/2023

  Repligen Corporation today reported financial results for its fourth quarter and full year 2022.

• Repligen Appoints Martin D. Madaus to Board of Directors

  2/9/2023

  Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

• Repligen to Report Fourth Quarter and Full Year 2022 Financial ResultsWebcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST

  2/8/2023

  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023.

• Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Repligen Corporation today announced that it will present at the 41st Annual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco.